Literature DB >> 31442571

Functionalized mesoporous silica nanoparticles in anticancer therapeutics.

Abul Barkat1, Sarwar Beg2, Sunil K Panda3, Khalid S Alharbi4, Mahfoozur Rahman5, Farhan J Ahmed6.   

Abstract

The application of nanomedicines in tumor targeting and attaining meaningful therapeutic benefits for the treatment of cancers has been going on for almost two decades. Beyond the lipidic and polymeric nanomedicines-based passive and active targeting, the quest for inventing the new generation of carriers has no end. This has lead to the evolution of some of the unique carrier systems with supramolecular assembly structures. Mesoporous nanoparticulate systems (MSNPs) are the recently explored substances with favorable potential for drug delivery and drug targeting applications especially in cancer chemotherapeutics. Notwithstanding their physical properties that makes them a suitable carrier for cancer treatment, but their outstanding ability towards chemical functionalization helps in delivering the imaging agents for diagnostic applications. MSNPs can improve the dissolution rate and systemic availability of the poorly water soluble drugs due to their mesoporous structures. Besides, guest molecules including targeting ligands, biomimetic agents, fluorescent dyes, and biocompatible polymers can be efficiently encapsulated in their tunable porous structure for targeting purpose. Some special features of the MSNPs which make them one of the highly effective nanocarrier systems include their ability to encapsulate non-crystalline drugs in their mesopores, high dispersion ability as a function of large surface area and wetting properties. For anticancer drug delivery, MSNPs are worthful to provide excellent drug loading capacity and endocytotic behavior. Moreover, the external surface of MSNPs can be precisely modified for tumor-recognition and developing sensitivity of the antitumor agents towards the cancer cells. Owing to the innumerable applications of MSNPs till now in cancer treatment, the present article particularly focuses to provide an overview account with complete details on the topic to make the readers abreast with details on physiochemical and material properties of MSNPs, their applications and current innovations for the purpose.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Drug delivery; Mesoporous carriers; Multimodal targeting; Nanoparticles

Mesh:

Substances:

Year:  2019        PMID: 31442571     DOI: 10.1016/j.semcancer.2019.08.022

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  7 in total

1.  Iron oxide nanoparticles as a drug carrier reduce host immunosuppression for enhanced chemotherapy.

Authors:  Benqing Zhou; Jinxing Liu; Lu Wang; Meng Wang; Chong Zhao; Haoyu Lin; Yuanke Liang; Rheal A Towner; Wei R Chen
Journal:  Nanoscale       Date:  2022-03-24       Impact factor: 7.790

2.  Drug-loaded oleic-acid grafted mesoporous silica nanoparticles conjugated with α-lactalbumin resembling BAMLET-like anticancer agent with improved biocompatibility and therapeutic efficacy.

Authors:  Wei Pei; Ling Cai; Xing Gong; Li Zhang; Jiarong Zhang; Ping Zhu; Huijun Jiang; Chao Wang; Shoulin Wang; Jin Chen
Journal:  Mater Today Bio       Date:  2022-05-04

Review 3.  Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy.

Authors:  Theodora Amanda Seidu; Perpetua Takunda Kutoka; Dorothy Owusu Asante; Muhammad Asim Farooq; Raphael N Alolga; Wang Bo
Journal:  Pharmaceutics       Date:  2022-05-23       Impact factor: 6.525

Review 4.  Development of Non-Porous Silica Nanoparticles towards Cancer Photo-Theranostics.

Authors:  Chihiro Mochizuki; Junna Nakamura; Michihiro Nakamura
Journal:  Biomedicines       Date:  2021-01-13

5.  Mesoporous silica-coated silver nanoparticles as ciprofloxacin/siRNA carriers for accelerated infected wound healing.

Authors:  Qiqi Liu; Ying Zhang; Jingkai Huang; Zhourui Xu; Xiang Li; Jingyu Yang; Haoqiang Huang; Shiqi Tang; Yujuan Chai; Jinbo Lin; Chengbin Yang; Jia Liu; Suxia Lin
Journal:  J Nanobiotechnology       Date:  2022-08-23       Impact factor: 9.429

Review 6.  Drug-loaded PEG-PLGA nanoparticles for cancer treatment.

Authors:  Dan Zhang; Lin Liu; Jian Wang; Hong Zhang; Zhuo Zhang; Gang Xing; Xuan Wang; Minghua Liu
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

Review 7.  siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.

Authors:  Saman Sargazi; Rabia Arshad; Reza Ghamari; Abbas Rahdar; Ali Bakhshi; Sonia Fathi Karkan; Narges Ajalli; Muhammad Bilal; Ana M Díez-Pascual
Journal:  Cell Biol Int       Date:  2022-07-13       Impact factor: 4.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.